Press Releases

pdficonAugust 23, 2017
Bioptix, Inc. Holds Special Shareholder Meeting

pdficonApril 10, 2017
Bioptix Announces Executive Leadership Change

pdficonJanuary 20, 2017
Bioptix Announces Streamlining of Workforce

pdficonJanuary 06, 2017
Bioptix Reports Board of Director Changes

pdficonDecember 08, 2016
Venaxis Reports Name Change to Bioptix, Inc and NASDAQ Ticker Symbol Change to “BIOP” from “APPY”

pdficonSeptember 23, 2016
Venaxis Reports Option Inducement Grants for New Employees Under NASDAQ Listing Rule 5635(c)(4)

pdficonSeptember 19, 2016
Venaxis Issues Shareholder Update

pdficonSeptember 13, 2016
Venaxis Announces Acquisition of BiOptix

pdficonMarch 14, 2016
Venaxis Announces Termination of Proposed Transactions with Strand Life Sciences

pdficonJanuary 26, 2016
Venaxis Announces Transaction With Strand Life Sciences

pdficonJune 22, 2015
Venaxis Business Update

pdficonApril 6, 2015
Venaxis Business Update

pdficonFeb 12, 2015
Venaxis Business Update

pdficonJan 29, 2015
Venaxis, Receives FDA “Not Substantially Equivalent” Response on APPY1 510(k) Submission

pdficonJan 6, 2015
Venaxis, Inc. to Present at Biotech Showcase™ 2015

pdficonDec 3, 2014
Venaxis Files Response to FDA’s Request for Additional Information

pdficonNov 13, 2014
Venaxis to Present at Canaccord Genuity 2014 Medical Technologies & Diagnostics Forum

pdficonOctober 27, 2014
Venaxis’  APPY1 Test  Trial Results  Presented by Dr. David S. Huckins, M.D., at ACEP14

pdficonOctober 14, 2014
Venaxis Announces APPY1 Test Clinical Trial Results to be Presented at ACEP14

pdficonAugust 28, 2014
Venaxis to Present at September Investor Conferences

pdficonAugust 11, 2014
Venaxis Announces Regulatory and Market Development Progress
Meeting with FDA Clarifies Path Forward

pdficonAugust 7, 2014
Venaxis to Provide Business Update, including FDA Submission Update
Conference Call and Webcast scheduled for August 11, 2014, 8:30 a.m. ET

pdficonAugust 5, 2014
Venaxis to Present at Canaccord Genuity 34th Annual Growth Conference

pdficonJuly 16, 2014
Venaxis Reports on Recent FDA Submission Activities

pdficonJuly 1, 2014
Venaxis to Present at ICV Company Outreach Summit